Study of of URC102 to Assess the Efficacy and Safety in Gout Patients

Summary

To confirm the safety and efficacy (dose response and optimal dose according to the serum uric acid response rate) of URC102 when orally-administered to patients with gout and gout-related hyperuricemia in comparison with placebo. Therapeutic dose-finding study, Placebo-controlled, randomized, double-blind, multicenter, phase 2 clinical trial.

Timeline

Start

2019-01-21

Primary completion

2020-09-04

Completion

2020-11-29

Publications

• Jun JB, Lee HS, Kim SH, Lee SG, Lim DH, Kim J, Park YB, Lim MJ, Hong SJ, Choi HJ, Lee SS, Kim HA, Hwang J, Suh CH, Han S, Choe JY, Yoo WH, Song JS. Efficacy and safety of epaminurad, a potent hURAT1 inhibitor, in patients with gout: a randomized, placebo-controlled, dose-finding study. Arthritis Res Ther. 2025 May 26;27(1):113. doi: 10.1186/s13075-025-03577-w.

Drugs

Indications